KPMG – Life Sciences CEO Outlook, 2024

KPMG's 2024 Life Sciences CEO Outlook reveals that 79% of life sciences CEOs are confident in their company's growth prospects. The report highlights that 60% of these CEOs consider generative AI their top investment priority, aiming to enhance research and development processes. However, only 43% believe they can meet their organization's net-zero goals by 2030, indicating challenges in achieving sustainability targets. Additionally, replacing retiring employees with skilled new ones is identified as the primary workforce challenge. The findings underscore the sector's focus on technological innovation and sustainability, alongside the need to address workforce dynamics.